Chemed Corporation Reports Strong Financial Performance with Stock Repurchases and Dividends

Summary

Chemed Corporation reported strong financial results for the period ending June 30, 2025, with a 21.3% CAGR in adjusted diluted EPS since 2003. The company repurchased 16.8 million shares at an average cost of $153.52 per share from 2007 to June 2025, returning $2.89 billion to shareholders through buybacks and dividends. In 2024, Chemed repurchased $358.7 million in shares and paid $27.1 million in dividends. For the first half of 2025, share repurchases totaled $72.7 million with $14.5 million in dividends, totaling $87.2 million returned to shareholders.Reuters

Impact Analysis

So basically, Chemed Corporation is demonstrating strong financial health and a commitment to returning value to shareholders. The 21.3% CAGR in adjusted diluted EPS since 2003 is impressive and indicates consistent growth. The significant share repurchases and dividends, totaling $2.89 billion since 2007, highlight a shareholder-friendly approach. The recent buybacks and dividends in 2024 and the first half of 2025 further reinforce this strategy. However, the mixed analyst ratings and recent volatility in the stock price suggest some market skepticism. The increased short interest and recent EPS miss could be weighing on sentiment. Despite this, the company’s low debt-to-equity ratio and strong financial management are positives. The market might be underestimating Chemed’s long-term potential, especially given its recession-ready positioning and undervaluation. Watching how the company navigates the current market conditions and any further updates on its VITAS hospice business will be crucial.Market Beat+ 5